Market Overview

Goldman Sachs Just Upgraded Mobileye To Buy, Sees Revenue Growth Through 2020


In a report published Thursday, Goldman Sachs analyst Alexander Duval upgraded shares of Mobileye NV (NYSE: MBLY) to Buy from Neutral with an unchanged $50 price target.

Duval noted that the PEG ratio has almost halved following recent weakness in the stock. In addition, shares have underperformed his EU tech coverage by around 13 percent year-to-date and around 45 percent since Mobileye shares peaked in October.

Duval added that the decline in shares is mostly due to technical factors, while fundamental factors including a 20 percent plus earnings per share beat in the third and fourth quarter and "significant" customer wins are major positives.

Duval also suggested that the "visibility" from long duration of contracts will support a 34 percent compounded annual growth rate in revenue for Mobiley through 2020.

The analyst estimated the company will control a 65 percent market share in 2020 and ship 15.7 million units, versus 2.7 million units shipped in 2014 and an estimated 4.2 million units in 2015.

Latest Ratings for MBLY

Apr 2017DowngradesOutperformNeutral
Mar 2017DowngradesOverweightNeutral
Mar 2017DowngradesBuyNeutral

View More Analyst Ratings for MBLY
View the Latest Analyst Ratings

Posted-In: Alexander Duval Assisted Driving Goldman Sachs PEG ratioAnalyst Color Upgrades Analyst Ratings


Related Articles (MBLY)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Credit Suisse Initiates NCI Building Systems With Outperform

Baxter's BioScience Unit Announces Positive Phase III Results for BAX 817